

Allan W Cripps

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6585489/publications.pdf>

Version: 2024-02-01

140
papers

5,421
citations

87888

38
h-index

91884

69
g-index

143
all docs

143
docs citations

143
times ranked

6352
citing authors

#	ARTICLE	IF	CITATIONS
1	The Gut Microbiome of Adults with Allergic Rhinitis Is Characterised by Reduced Diversity and an Altered Abundance of Key Microbial Taxa Compared to Controls. <i>International Archives of Allergy and Immunology</i> , 2021, 182, 94-105.	2.1	24
2	Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence. <i>Expert Review of Vaccines</i> , 2021, 20, 243-256.	4.4	33
3	Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature. <i>Expert Review of Vaccines</i> , 2021, 20, 257-267.	4.4	10
4	Differences in Pneumococcal and Haemophilus influenzae Natural Antibody Development in Papua New Guinean Children in the First Year of Life. <i>Frontiers in Immunology</i> , 2021, 12, 725244.	4.8	5
5	The impact of the changing pneumococcal national immunisation program among older Australians. <i>Vaccine</i> , 2021, 39, 720-728.	3.8	6
6	Adult allergic rhinitis sufferers have unique nasal mucosal and peripheral blood immune gene expression profiles: A case-control study. <i>Immunity, Inflammation and Disease</i> , 2021, 10, 78.	2.7	6
7	Innate Immunity in the Middle Ear Mucosa. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 764772.	3.9	7
8	Nasal immune gene expression in response to azelastine and fluticasone propionate combination or monotherapy. <i>Immunity, Inflammation and Disease</i> , 2021, . .	2.7	1
9	Immunological characterisation of truncated lipooligosaccharide-outer membrane protein based conjugate vaccine against <i>Moraxella catarrhalis</i> and nontypeable <i>Haemophilus influenzae</i> . <i>Vaccine</i> , 2020, 38, 309-317.	3.8	3
10	Fucoidan Supplementation Restores Fecal Lysozyme Concentrations in High-Performance Athletes: A Pilot Study. <i>Marine Drugs</i> , 2020, 18, 412.	4.6	13
11	Pharmacokinetic modeling to determine the minimum effective dose of disease-specific antibodies for preventing hepatitis A post-exposure. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 641-644.	3.3	0
12	Probiotics, Anticipation Stress, and the Acute Immune Response to Night Shift. <i>Frontiers in Immunology</i> , 2020, 11, 599547.	4.8	13
13	Cancerbiome: Defining a healthy microbiome for therapeutic targeting.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15152-e15152.	1.6	0
14	Key viral immune genes and pathways identify elite athletes with URS. <i>Exercise Immunology Review</i> , 2020, 26, 56-78.	0.4	1
15	Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia. <i>Vaccine</i> , 2019, 37, 3141.	3.8	2
16	Modulation of Allergic Inflammation in the Nasal Mucosa of Allergic Rhinitis Sufferers With Topical Pharmaceutical Agents. <i>Frontiers in Pharmacology</i> , 2019, 10, 294.	3.5	65
17	<p>An Oral Whole-Cell Killed Nontypeable Haemophilus influenzae Immunotherapeutic For The Prevention Of Acute Exacerbations Of Chronic Airway Disease</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 2423-2431.	2.3	5
18	Paediatric and adult bronchiectasis: Vaccination in prevention and management. <i>Respirology</i> , 2019, 24, 107-114.	2.3	6

#	ARTICLE	IF	CITATIONS
19	Recovery of <i>Lactobacillus casei</i> strain Shirota (LcS) from faeces with 14 days of fermented milk supplementation in healthy Australian adults. <i>Asia Pacific Journal of Clinical Nutrition</i> , 2019, 28, 734-739.	0.4	5
20	Upper Respiratory Symptoms, Gut Health and Mucosal Immunity in Athletes. <i>Sports Medicine</i> , 2018, 48, 65-77.	6.5	59
21	Non-typeable <i>Haemophilus Influenzae</i> detection in the lower airways of patients with lung cancer and chronic obstructive pulmonary disease. <i>Multidisciplinary Respiratory Medicine</i> , 2018, 13, 11.	1.5	11
22	Nontypeable <i>Haemophilus influenzae</i> and chronic obstructive pulmonary disease: a review for clinicians. <i>Critical Reviews in Microbiology</i> , 2018, 44, 125-142.	6.1	44
23	Enteroendocrine and adipokine associations with type 2 diabetes: Phenotypic risk scoring approaches. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1357-1364.	2.8	4
24	Gene expression profiles in whole blood and associations with metabolic dysregulation in obesity. <i>Obesity Research and Clinical Practice</i> , 2018, 12, 204-213.	1.8	3
25	Combination of Principal Component Analysis and Genetic Algorithm for Microbial Biomarker Identification in Obesity. , 2018, , .		1
26	A Specifically Designed Multispecies Probiotic Supplement Relieves Seasonal Allergic Rhinitis Symptoms. <i>Journal of Alternative and Complementary Medicine</i> , 2018, 24, 833-840.	2.1	13
27	The clinical, immunological and microbiological impact of the 10-valent pneumococcal-Protein D conjugate vaccine in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: A multi-centre, double-blind, randomised controlled trial. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1-12.	3.3	11
28	The optimal dose of disease-specific antibodies for post-exposure prophylaxis of measles and rubella in Australia: new guidelines recommended. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 663-669.	3.3	4
29	Distinct Gene Expression Patterns between Nasal Mucosal Cells and Blood Collected from Allergic Rhinitis Sufferers. <i>International Archives of Allergy and Immunology</i> , 2018, 177, 29-34.	2.1	9
30	The <i>Streptococcus agalactiae</i> virulence regulator CovR affects the pathogenesis of urinary tract infection. <i>Journal of Infectious Diseases</i> , 2017, 215, jiw589.	4.0	24
31	Rubella antibodies in Australian immunoglobulin products. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1952-1955.	3.3	4
32	The gut microbiome and inflammatory profiling in athlete health. <i>Journal of Science and Medicine in Sport</i> , 2017, 20, e81.	1.3	2
33	Oral supplementation with bovine whey-derived Ig-rich fraction and lactoferrin improves SCORAD and DLQI in atopic dermatitis. <i>Journal of Dermatological Science</i> , 2017, 85, 143-146.	1.9	7
34	Effects of short-term supplementation with bovine lactoferrin and/or immunoglobulins on body mass and metabolic measures: a randomised controlled trial. <i>International Journal of Food Sciences and Nutrition</i> , 2017, 68, 219-226.	2.8	2
35	Do Australian immunoglobulin products meet international measles antibody titer standards?. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 607-612.	3.3	11
36	Integrated biomedical data analysis utilizing various types of data for biomarkers identification. , 2017, , .		4

#	ARTICLE	IF	CITATIONS
37	Urinary tract infection of mice to model human disease: Practicalities, implications and limitations. <i>Critical Reviews in Microbiology</i> , 2016, 42, 1-20.	6.1	43
38	Effect of acupuncture on house dust mite specific IgE, substance P, and symptoms in persistent allergic rhinitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 116, 497-505.	1.0	25
39	Probiotics and Allergic Rhinitis: A Simon Two-Stage Design to Determine Effectiveness. <i>Journal of Alternative and Complementary Medicine</i> , 2016, 22, 1007-1012.	2.1	10
40	Pathogenesis of Streptococcus urinary tract infection depends on bacterial strain and β -hemolysin/cytolysin that mediates cytotoxicity, cytokine synthesis, inflammation and virulence. <i>Scientific Reports</i> , 2016, 6, 29000.	3.3	59
41	Otitis media. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16063.	30.5	332
42	Aboriginal and non-Aboriginal children in Western Australia carry different serotypes of pneumococci with different antimicrobial susceptibility profiles. <i>Pneumonia (Nathan Qld)</i> , 2016, 8, 15.	6.1	6
43	Discovery and Characterization of Human-Urine Utilization by Asymptomatic-Bacteriuria-Causing <i>Streptococcus agalactiae</i> . <i>Infection and Immunity</i> , 2016, 84, 307-319.	2.2	24
44	Predominant Bacteria Detected from the Middle Ear Fluid of Children Experiencing Otitis Media: A Systematic Review. <i>PLoS ONE</i> , 2016, 11, e0150949.	2.5	184
45	Questionnaire validation: Retrospective analysis of clinical data. <i>Clinical Nutrition</i> , 2015, 34, 1283.	5.0	0
46	Mediators, Receptors, and Signalling Pathways in the Anti-Inflammatory and Antihyperalgesic Effects of Acupuncture. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-10.	1.2	41
47	Ontogeny of Mucosal Immunity and Aging. , 2015, , 161-185.		8
48	Vaccination against respiratory <i>Pseudomonas aeruginosa</i> infection. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 14-20.	3.3	62
49	Probiotics supplementation for athletes – Clinical and physiological effects. <i>European Journal of Sport Science</i> , 2015, 15, 63-72.	2.7	87
50	Obesity, inflammation, and the gut microbiota. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 207-215.	11.4	617
51	Immunity, immunopathology, and human vaccine development against sexually transmitted <i>Chlamydia trachomatis</i> . <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2664-2673.	3.3	30
52	Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals. <i>Clinical Nutrition</i> , 2014, 33, 581-587.	5.0	125
53	Supplementation with a single and double strain probiotic on the innate immune system for respiratory illness. <i>E-SPEN Journal</i> , 2014, 9, e178-e184.	0.5	10
54	Non-typeable <i>Haemophilus influenzae</i> , an under-recognised pathogen. <i>Lancet Infectious Diseases</i> , 2014, 14, 1281-1292.	9.1	277

#	ARTICLE	IF	CITATIONS
55	Volume 5 Editor's Forward. <i>Pneumonia</i> (Nathan Qld), 2014, 5, i-i.	6.1	0
56	HIV epidemic in men who have sex with men in Philippines. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 472-473.	9.1	24
57	Probiotics and Immune Response to Exercise. <i>American Journal of Lifestyle Medicine</i> , 2013, 7, 51-59.	1.9	7
58	Enteropathogens and Chronic Illness in Returning Travelers. <i>New England Journal of Medicine</i> , 2013, 368, 1817-1825.	27.0	120
59	Peripheral blood natural killer (NK) cell function in healthy adults assessed using the target-induced NK loss (TINKL) assay. <i>Journal of Immunological Methods</i> , 2013, 392, 68-70.	1.4	2
60	Mucosal and systemic antibody responses to potential <i>Pseudomonas aeruginosa</i> vaccine protein antigens in young children with cystic fibrosis following colonization and infection. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 506-514.	3.3	24
61	Enteropathogens and Chronic Illness in Returning Travelers. <i>New England Journal of Medicine</i> , 2013, 369, 783-784.	27.0	10
62	Epitope-specific immune recognition of the nontypeable <i>Haemophilus influenzae</i> outer membrane protein 26. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 625-635.	3.3	5
63	Are vaccination models suitable to determine whether probiotics have beneficial health effects in the general population?. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 621-624.	3.3	9
64	Passive immunization for the public health control of communicable diseases: Current status in four high-income countries and where to next. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1885-1893.	3.3	11
65	Vaccination for the control of childhood bacterial pneumonia – <i>Haemophilus influenzae</i> type b and pneumococcal vaccines. <i>Pneumonia</i> (Nathan Qld), 2013, 2, 2-15.	6.1	7
66	Welcome to pneumonia Volume 2. <i>Pneumonia</i> (Nathan Qld), 2013, 2, 1-1.	6.1	0
67	Delivering vaccines for the prevention of pneumonia – programmatic and financial issues. <i>Pneumonia</i> (Nathan Qld), 2013, 2, 16-25.	6.1	3
68	Innate Transcriptional Networks Activated in Bladder in Response to Uropathogenic <i>Escherichia coli</i> Drive Diverse Biological Pathways and Rapid Synthesis of IL-10 for Defense against Bacterial Urinary Tract Infection. <i>Journal of Immunology</i> , 2012, 188, 781-792.	0.8	87
69	Gut Balance, a synbiotic supplement, increases fecal <i>Lactobacillus paracasei</i> but has little effect on immunity in healthy physically active individuals. <i>Gut Microbes</i> , 2012, 3, 221-227.	9.8	43
70	Genome-Wide Mapping of Cystitis Due to <i>Streptococcus agalactiae</i> and <i>Escherichia coli</i> in Mice Identifies a Unique Bladder Transcriptome That Signifies Pathogen-Specific Antimicrobial Defense against Urinary Tract Infection. <i>Infection and Immunity</i> , 2012, 80, 3145-3160.	2.2	46
71	Welcome to pneumonia.org.au. <i>Pneumonia</i> (Nathan Qld), 2012, 1, 1-2.	6.1	3
72	<i>Haemophilus influenzae</i> and smoking-related obstructive airways disease. <i>International Journal of COPD</i> , 2011, 6, 345.	2.3	9

#	ARTICLE	IF	CITATIONS
73	Mucosal Immunization with the Moraxella Catarrhalis Porin M35 Induces Enhanced Bacterial Clearance from the Lung: A Possible Role for Opsonophagocytosis. <i>Frontiers in Immunology</i> , 2011, 2, 13.	4.8	8
74	New strategies for cancer gene therapy: Progress and opportunities. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2010, 37, 108-114.	1.9	40
75	Developmental Profiles of Mucosal Immunity in Pre-school Children. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-10.	3.3	9
76	Mucosal immunization: A realistic alternative. <i>Hum Vaccin</i> , 2010, 6, 978-1006.	2.4	42
77	Nontypeable Haemophilus influenzae and childhood pneumonia. <i>Papua and New Guinea Medical Journal</i> , 2010, 53, 147-50.	1.0	6
78	Otitis media: viruses, bacteria, biofilms and vaccines. <i>Medical Journal of Australia</i> , 2009, 191, S44-9.	1.7	67
79	The incidence of Streptococcus pneumoniae otitis media is affected by the polymicrobial environment particularly Moraxella catarrhalis in a mouse nasal colonisation model. <i>Microbes and Infection</i> , 2009, 11, 545-553.	1.9	43
80	Mucosal immunization for bacterial respiratory infections. <i>Hum Vaccin</i> , 2008, 4, 396-399.	2.4	2
81	<i>Moraxella catarrhalis</i> M35 Is a General Porin That Is Important for Growth under Nutrient-Limiting Conditions and in the Nasopharynxes of Mice. <i>Journal of Bacteriology</i> , 2008, 190, 7994-8002.	2.2	14
82	The relationship between undernutrition and humoral immune status in children with pneumonia in Papua New Guinea. <i>Papua and New Guinea Medical Journal</i> , 2008, 51, 120-30.	1.0	8
83	Optimisation of Oral Immunization Through Receptor-Mediated Targeting of M Cells. <i>Hum Vaccin</i> , 2007, 3, 220-223.	2.4	11
84	Bacterial ghosts as adjuvant particles. <i>Expert Review of Vaccines</i> , 2007, 6, 241-253.	4.4	71
85	Prospects for a vaccine against otitis media. <i>Expert Review of Vaccines</i> , 2006, 5, 517-534.	4.4	50
86	Pneumococcal vaccination in developing countries. <i>Lancet, The</i> , 2006, 368, 644.	13.7	11
87	Enterocyte and M-Cell Transport of Native and Heat-Denatured Bovine β -Lactoglobulin: Significance of Heat Denaturation. <i>Journal of Agricultural and Food Chemistry</i> , 2006, 54, 1500-1507.	5.2	28
88	Safety and Immunogenicity of an Oral Inactivated Whole-Cell Pseudomonas aeruginosa Vaccine Administered to Healthy Human Subjects. <i>Infection and Immunity</i> , 2006, 74, 968-974.	2.2	43
89	Microbial Pattern Recognition Receptors Mediate M-Cell Uptake of a Gram-Negative Bacterium. <i>Infection and Immunity</i> , 2006, 74, 625-631.	2.2	90
90	Characterization of a Novel Porin Protein from Moraxella catarrhalis and Identification of an Immunodominant Surface Loop. <i>Journal of Bacteriology</i> , 2005, 187, 6528-6535.	2.2	22

#	ARTICLE	IF	CITATIONS
91	Bacterial otitis media: a vaccine preventable disease?. <i>Vaccine</i> , 2005, 23, 2304-2310.	3.8	60
92	Development of mucosal immunity in the first year of life and relationship to sudden infant death syndrome. <i>FEMS Immunology and Medical Microbiology</i> , 2004, 42, 21-33.	2.7	44
93	Bacterial otitis media: Current vaccine development strategies. <i>Immunology and Cell Biology</i> , 2003, 81, 46-51.	2.3	32
94	Mucosal immunization against respiratory bacterial pathogens. <i>Expert Review of Vaccines</i> , 2003, 2, 551-560.	4.4	18
95	Efficacy of the 26-Kilodalton Outer Membrane Protein and Two P5 Fimbrin-Derived Immunogens To Induce Clearance of Nontypeable <i>Haemophilus influenzae</i> from the Rat Middle Ear and Lungs as Well as from the Chinchilla Middle Ear and Nasopharynx. <i>Infection and Immunity</i> , 2003, 71, 4691-4699.	2.2	55
96	Validation and quantitation of an in vitro M-cell model. <i>Biochemical and Biophysical Research Communications</i> , 2002, 299, 377-383.	2.1	46
97	Challenges for the development of vaccines against <i>Haemophilus influenzae</i> and <i>Neisseria meningitidis</i> . <i>Current Opinion in Immunology</i> , 2002, 14, 553-557.	5.5	11
98	Viral Co-Infection Does Not Reduce the Efficacy of Vaccination against Non-Typeable <i>Haemophilus influenzae</i> Middle Ear Infection in a Rat Model. <i>Orl</i> , 2001, 63, 96-101.	1.1	4
99	CD8 ⁺ T Cells Have an Essential Role in Pulmonary Clearance of Nontypeable <i>Haemophilus influenzae</i> following Mucosal Immunization. <i>Infection and Immunity</i> , 2001, 69, 2636-2642.	2.2	17
100	Studies on the IgA-independent immunological responses in mice to influenza virus challenge after oral vaccination with irradiated whole virus and an erythrocyte complex. <i>Immunology and Cell Biology</i> , 2000, 78, 149-155.	2.3	2
101	A P5 Peptide That Is Homologous to Peptide 10 of OprF from <i>Pseudomonas aeruginosa</i> Enhances Clearance of Nontypeable <i>Haemophilus influenzae</i> from Acutely Infected Rat Lung in the Absence of Detectable Peptide-Specific Antibody. <i>Infection and Immunity</i> , 2000, 68, 377-381.	2.2	15
102	Identifying vaccine antigens and assessing delivery systems for the prevention of bacterial infections. <i>Journal of Biotechnology</i> , 2000, 83, 85-90.	3.8	15
103	Towards a Protein Vaccine for Nontypeable <i>Haemophilus influenzae</i> . <i>Clinical Infectious Diseases</i> , 1999, 28, 238-238.	5.8	8
104	Introduction: Acute Respiratory Tract Infections – The Forgotten Pandemic. <i>Clinical Infectious Diseases</i> , 1999, 28, 189-191.	5.8	29
105	Nontypeable <i>Haemophilus influenzae</i> : challenges in developing a vaccine. <i>Journal of Biotechnology</i> , 1999, 73, 103-108.	3.8	19
106	A Method for the Purification and Refolding of a Recombinant Form of the Nontypeable <i>Haemophilus influenzae</i> P5 Outer Membrane Protein Fused to Polyhistidine. <i>Protein Expression and Purification</i> , 1999, 15, 1-7.	1.3	14
107	Salivary IgA levels and infection risk in elite swimmers. <i>Medicine and Science in Sports and Exercise</i> , 1999, 31, 67-73.	0.4	251
108	Immunization with Recombinant Transferrin Binding Protein B Enhances Clearance of Nontypeable <i>Haemophilus influenzae</i> from the Rat Lung. <i>Infection and Immunity</i> , 1999, 67, 2138-2144.	2.2	33

#	ARTICLE	IF	CITATIONS
109	Characterization of the Gene Encoding a 26-Kilodalton Protein (OMP26) from Nontypeable Haemophilus influenzae and Immune Responses to the Recombinant Protein. <i>Infection and Immunity</i> , 1999, 67, 1935-1942.	2.2	9
110	Characteristics of the immunological response in the clearance of non-typeable Haemophilus influenzae from the lung. <i>Immunology and Cell Biology</i> , 1998, 76, 323-331.	2.3	13
111	Kinetics of inflammatory cytokines in the clearance of non-typeable Haemophilus influenzae from the lung. <i>Immunology and Cell Biology</i> , 1998, 76, 556-559.	2.3	13
112	Potential of a Novel Protein, OMP26, from Nontypeable Haemophilus influenzae To Enhance Pulmonary Clearance in a Rat Model. <i>Infection and Immunity</i> , 1998, 66, 2272-2278.	2.2	54
113	Nontypeable Haemophilus influenzae: Pathogenesis and Prevention. <i>Microbiology and Molecular Biology Reviews</i> , 1998, 62, 294-308.	6.6	207
114	Protection against non-typeable Haemophilus influenzae following sensitization of gut associated lymphoid tissue: Role of specific antibody and phagocytes. <i>Immunology and Cell Biology</i> , 1995, 73, 258-265.	2.3	10
115	Modifiers of the human mucosal immune system. <i>Immunology and Cell Biology</i> , 1995, 73, 397-404.	2.3	73
116	Acute on chronic bronchitis: A model of mucosal immunology. <i>Immunology and Cell Biology</i> , 1995, 73, 414-417.	2.3	15
117	Pulmonary immunity to Pseudomonas aeruginosa. <i>Immunology and Cell Biology</i> , 1995, 73, 418-424.	2.3	45
118	Activation of the Neutrophil Bactericidal Activity for Nontypable Haemophilus influenzae by Tumor Necrosis Factor and Lymphotoxin. <i>Pediatric Research</i> , 1995, 37, 155-159.	2.3	35
119	An assessment of mucosal immunisation in protection against Streptococcus equi (Strangles) infections in horses. <i>Veterinary Immunology and Immunopathology</i> , 1995, 48, 139-154.	1.2	8
120	Detection of Antibody against Helicobacter pylori in the Saliva of Patients with Dyspepsia. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 1994, 8, 408-412.	1.7	8
121	An alteration in the host-parasite relationship in subjects with chronic bronchitis prone to recurrent episodes of acute bronchitis. <i>Immunology and Cell Biology</i> , 1994, 72, 143-151.	2.3	22
122	The Immuno-evasive Activities of Pseudomonas aeruginosa: Relevance for Cystic Fibrosis. <i>The American Review of Respiratory Disease</i> , 1993, 148, 793-805.	2.9	90
123	Mucosal Immune Response in a Case of Sudden Infant Death Syndrome. <i>Pediatric Research</i> , 1993, 33, 554-556.	2.3	34
124	Specific Protection against Acute Bronchitis Associated with Nontypeable Haemophilus influenzae. <i>Journal of Infectious Diseases</i> , 1992, 165, S194-S195.	4.0	18
125	Measurement of lysozyme by an enzyme-linked immunosorbent assay. <i>Journal of Immunological Methods</i> , 1992, 146, 55-61.	1.4	26
126	C-reactive protein: A critical review. <i>Pathology</i> , 1991, 23, 118-124.	0.6	261

#	ARTICLE	IF	CITATIONS
127	Reduction in the Incidence of Acute Bronchitis by an Oral <i>Haemophilus influenzae</i> Vaccine in Patients with Chronic Bronchitis in the Highlands of Papua New Guinea. <i>The American Review of Respiratory Disease</i> , 1991, 144, 324-330.	2.9	59
128	Ontogeny of the Mucosal Immune Response in Children. <i>Advances in Experimental Medicine and Biology</i> , 1991, 310, 87-92.	1.6	25
129	Evaluation of a selective medium for the isolation and differentiation of <i>Haemophilus Influenzae</i> and <i>Haemophilus Parainfluenzae</i> from the respiratory tract of chronic bronchitics. <i>Pathology</i> , 1990, 22, 162-164.	0.6	1
130	The handling of inhaled antigen within the respiratory tract. <i>Advanced Drug Delivery Reviews</i> , 1990, 5, 63-72.	13.7	4
131	Protection against recurrent acute bronchitis after oral immunization with killed <i>Haemophilus influenzae</i> . <i>Medical Journal of Australia</i> , 1990, 152, 413-416.	1.7	37
132	An Animal Model Demonstration of Enhanced Clearance of Nontypable <i>Haemophilus influenzae</i> from the Respiratory Tract after Antigen Stimulation of Gut-associated Lymphoid Tissue. <i>The American Review of Respiratory Disease</i> , 1989, 140, 311-316.	2.9	82
133	Biotyping respiratory <i>Haemophilus</i> species with the microbact system. <i>Pathology</i> , 1988, 20, 253-255.	0.6	5
134	ORAL IMMUNISATION WITH KILLED HAEMOPHILUS INFLUENZAE FOR PROTECTION AGAINST ACUTE BRONCHITIS IN CHRONIC OBSTRUCTIVE LUNG DISEASE. <i>Lancet, The</i> , 1985, 326, 1395-1397.	13.7	97
135	RESTRICTIONS ON MUCOSAL B-LYMPHOCYTE FUNCTION IN MAN. <i>Annals of the New York Academy of Sciences</i> , 1983, 409, 745-750.	3.8	11
136	A Microassay for Detecting Merozoite Inhibition Suitable for Routine Laboratory use *. <i>American Journal of Tropical Medicine and Hygiene</i> , 1983, 32, 6-10.	1.4	4
137	Lyme arthritis in the Hunter Valley. <i>Medical Journal of Australia</i> , 1982, 1, 139-139.	1.7	78
138	DETECTION OF AN IMMUNOSUPPRESSIVE FACTOR IN HUMAN PREIMPLANTATION EMBRYO CULTURES. <i>Medical Journal of Australia</i> , 1981, 1, 78-79.	1.7	33
139	Early pregnancy factor: its role in mammalian reproduction—research review. <i>Fertility and Sterility</i> , 1981, 35, 397-402.	1.0	37
140	The use of normal human immunoglobulin (NHIG) for public health purposes in Queensland 2004-2014 and Australia 2014-2016. <i>Communicable Diseases Intelligence</i> (2018), 0, 43, .	0.7	0